CN102046638B - 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 - Google Patents

检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 Download PDF

Info

Publication number
CN102046638B
CN102046638B CN200980119032.0A CN200980119032A CN102046638B CN 102046638 B CN102046638 B CN 102046638B CN 200980119032 A CN200980119032 A CN 200980119032A CN 102046638 B CN102046638 B CN 102046638B
Authority
CN
China
Prior art keywords
certain embodiments
present
compound
relates
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980119032.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102046638A (zh
Inventor
D·R·埃尔马勒
T·肖普
H·付
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Fluoropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Fluoropharma Inc filed Critical General Hospital Corp
Priority to CN201510221345.4A priority Critical patent/CN104974024B/zh
Publication of CN102046638A publication Critical patent/CN102046638A/zh
Application granted granted Critical
Publication of CN102046638B publication Critical patent/CN102046638B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/192—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/21—Acetic acid esters of hydroxy compounds with more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN200980119032.0A 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 Expired - Fee Related CN102046638B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510221345.4A CN104974024B (zh) 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3857108P 2008-03-21 2008-03-21
US61/038571 2008-03-21
PCT/US2009/037928 WO2009117728A2 (en) 2008-03-21 2009-03-23 Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510221345.4A Division CN104974024B (zh) 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Publications (2)

Publication Number Publication Date
CN102046638A CN102046638A (zh) 2011-05-04
CN102046638B true CN102046638B (zh) 2015-06-03

Family

ID=41091569

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980119032.0A Expired - Fee Related CN102046638B (zh) 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
CN201510221345.4A Expired - Fee Related CN104974024B (zh) 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510221345.4A Expired - Fee Related CN104974024B (zh) 2008-03-21 2009-03-23 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Country Status (8)

Country Link
US (5) US8450466B2 (https=)
EP (2) EP3231804B1 (https=)
JP (3) JP5501339B2 (https=)
CN (2) CN102046638B (https=)
AU (1) AU2009225407B2 (https=)
CA (2) CA2978149C (https=)
MX (2) MX375108B (https=)
WO (1) WO2009117728A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2807683C (en) * 2010-08-16 2020-02-18 Cognoptix, Inc. System and method for detecting amyloid proteins
WO2012099904A1 (en) * 2011-01-18 2012-07-26 General Atomics Hydrolase enzyme substrates and uses thereof
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
AU2015231239B2 (en) 2014-03-19 2018-11-29 Amydis, Inc. Amyloid targeting agents and methods of using the same
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
JP6765518B2 (ja) 2016-09-29 2020-10-07 コリア アトミック エナジー リサーチ インスティテュートＫｏｒｅａ Ａｔｏｍｉｃ Ｅｎｅｒｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ クルクミン誘導体、その製造方法、及びそれを含むベータ−アミロイドプラーク検出用光音響イメージング剤
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
MA52796A (fr) 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
JPWO2022059776A1 (https=) * 2020-09-17 2022-03-24
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
IL314660A (en) * 2022-02-07 2024-09-01 Martin J Moskovitz Cryosurgical device and materials and methods for its use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000171A1 (fr) * 1983-06-27 1985-01-17 Sandoz Ag Spiroxuccinimides, leur fabrication et leur utilisation
US4804665A (en) * 1986-12-27 1989-02-14 Takeda Chemical Industries, Ltd. Azaspiro compounds and their use
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US20060117397A1 (en) * 2004-11-05 2006-06-01 Wyeth Imaging modalities for screening Alzheimer's disease therapeutics

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009897A (en) 1911-03-27 1911-11-28 Us Electrographic Company Projection apparatus.
CH375356A (de) * 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
CH449628A (de) * 1962-04-16 1968-01-15 Sandoz Ag Verfahren zur Herstellung substituierter Succinimide
US3207780A (en) * 1962-11-15 1965-09-21 Upjohn Co 1-deoxy-1-guanidino-3-o-carbamoyl-scyllo-inositol and acylates thereof
US4069262A (en) 1977-03-07 1978-01-17 E. I. Du Pont De Nemours And Company Preparation of 2-fluoronitrobenzene
FR2498594A1 (fr) 1981-01-23 1982-07-30 Rhone Poulenc Ind Procede de preparation de monoesters d'acides carboxyliques b,g-insatures
US4446123A (en) 1982-10-13 1984-05-01 Hahnemann University Process of radioimaging the myocardium of mammals utilizing radiolabeled lipophilic cations
BE900003A (fr) * 1983-06-27 1984-12-27 Sandoz Sa Derives du spirosuccinimide utilisables comme medicaments.
US4606908A (en) 1983-10-04 1986-08-19 Washington Research Foundation Methods and compositions for plasma and organ imaging
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE9002117L (sv) 1990-06-14 1991-08-26 Nils Elander Mikrovaagsanordning foer behandling av precessvaetskor
US5139034A (en) * 1990-11-15 1992-08-18 Philip Morris Incorporated Smoking compositions containing a menthol-release additive
IT1244546B (it) * 1991-02-01 1994-07-15 Mediolanum Farmaceutici Spa Analoghi del fosfatidilinositolo inibitori della fosfolipasi c fosfatidilinositolo-specifica
US5315043A (en) 1992-02-05 1994-05-24 E. I. Du Pont De Nemours And Company Aromatic nucleophilic fluorination
US5264570A (en) * 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6001331A (en) 1996-01-24 1999-12-14 Warner-Lambert Company Method of imaging amyloid deposits
JP3816570B2 (ja) * 1996-02-16 2006-08-30 塩水港精糖株式会社 アシル化剤
TW593290B (en) 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
DE19624705A1 (de) * 1996-06-20 1998-01-08 Deutsches Krebsforsch Dendrimere auf Saccharid-Basis
US5817877A (en) 1996-09-23 1998-10-06 Yale University Metal-catalyzed amination of organic sulfonates to organic amines
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
WO1999012579A1 (en) 1997-09-08 1999-03-18 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
JP4177472B2 (ja) * 1997-10-02 2008-11-05 株式会社横浜国際バイオ研究所 窒素官能基を含有するアシル化剤及びその製造法
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
JP4116793B2 (ja) 1999-09-13 2008-07-09 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
EP1294663B1 (en) 2000-06-12 2004-05-06 University of Florida Research Foundation Fluorinated benzene manufacturing process
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
EP1474177A4 (en) 2002-02-06 2010-07-21 Univ Johns Hopkins NONINVASIVE DIAGNOSTIC IMAGING TECHNOLOGY FOR MITOCHONDRIA USING LIPOPHILER SALTS
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7295831B2 (en) 2003-08-12 2007-11-13 3E Technologies International, Inc. Method and system for wireless intrusion detection prevention and security management
WO2005016384A1 (ja) 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
EP2388017B1 (en) 2004-02-24 2014-12-24 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
EP1824496A4 (en) 2004-11-17 2008-07-16 Joanne Mclaurin COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
US7138540B1 (en) 2005-09-06 2006-11-21 Institute Of Nuclear Energy Research Convenient method for the preparation of new precursor of no-carrier-added O-(2-[18F]fluoroethyl)-L-Tyrosine)
WO2007041855A1 (en) * 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
JP2007194369A (ja) * 2006-01-18 2007-08-02 Toei Kogyo Kk 高出力Ｅｒ：ＹＡＧレーザ装置
NO325976B1 (no) * 2006-01-26 2008-08-25 Gba Marine As Anordning for absorpsjon av gass eller damp i vaeske og fremgangsmate ved reintrodusering av damp eller gass i vaeske som gassen eller dampen stammer fra
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
JP2010520229A (ja) 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
JPWO2009014203A1 (ja) * 2007-07-26 2010-10-07 北興化学工業株式会社 （１，３，５／２，４，６）−１−フルオロ−２，３，４，５，６−シクロヘキサンペントールの製造方法
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
WO2010072342A2 (en) 2008-12-22 2010-07-01 Bayer Schering Pharma Aktiengesellschaft A method for the synthesis of a radionuclide-labeled compound
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014052454A1 (en) 2012-09-25 2014-04-03 The Regents Of The University Of Michigan Imaging agents
WO2016070074A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation F-18 labeled tracer and methods of manufacture

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000171A1 (fr) * 1983-06-27 1985-01-17 Sandoz Ag Spiroxuccinimides, leur fabrication et leur utilisation
US4804665A (en) * 1986-12-27 1989-02-14 Takeda Chemical Industries, Ltd. Azaspiro compounds and their use
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US20060117397A1 (en) * 2004-11-05 2006-06-01 Wyeth Imaging modalities for screening Alzheimer's disease therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
regiospezifische reduktionen von 1,3,3-trisubstituierten succinimiden mit diboran//regiospecific reduction of 1,3,3-trisubstituted succinimides by diborane;sueess R;《helvetica chimica acta》;19771231;第60卷(第5期);1650-1656 *

Also Published As

Publication number Publication date
CN102046638A (zh) 2011-05-04
CA2718035C (en) 2017-10-24
MX375108B (es) 2025-03-06
WO2009117728A3 (en) 2010-02-18
JP5501339B2 (ja) 2014-05-21
JP2014177457A (ja) 2014-09-25
WO2009117728A2 (en) 2009-09-24
CA2718035A1 (en) 2009-09-24
US10857247B2 (en) 2020-12-08
US20150098903A1 (en) 2015-04-09
CA2978149A1 (en) 2009-09-24
US20190381199A1 (en) 2019-12-19
US20110060138A1 (en) 2011-03-10
AU2009225407B2 (en) 2013-09-05
CN104974024B (zh) 2017-11-14
EP2268647B1 (en) 2017-01-25
JP2017075173A (ja) 2017-04-20
EP3231804A1 (en) 2017-10-18
EP2268647A4 (en) 2011-05-18
US20130315827A1 (en) 2013-11-28
CA2978149C (en) 2019-02-12
US20210338849A1 (en) 2021-11-04
CN104974024A (zh) 2015-10-14
HK1157323A1 (en) 2012-06-29
US8450466B2 (en) 2013-05-28
HK1217100A1 (zh) 2016-12-23
EP3231804B1 (en) 2021-03-03
JP6370361B2 (ja) 2018-08-08
AU2009225407A1 (en) 2009-09-24
JP6140090B2 (ja) 2017-05-31
MX2010010314A (es) 2011-04-12
US9005578B2 (en) 2015-04-14
EP2268647A2 (en) 2011-01-05
JP2011515417A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
CN102046638B (zh) 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
JP5976206B2 (ja) 神経機能障害を検出するための造影剤
US8558003B2 (en) Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
JP2011512354A (ja) 神経機能障害を検知するための新規の造影剤
US20120189547A1 (en) [18f] labelled analogues of flumazenil as in vivo imaging agents
AU2013248197B2 (en) Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
HK1217100B (en) Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
HK1157323B (en) Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
AU2016213801A1 (en) Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
JP2021102593A (ja) タウを画像化する新規化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157323

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1157323

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20161222

Address after: Massachusetts, USA

Patentee after: THE GENERAL Hospital Corp.

Address before: Massachusetts, USA

Patentee before: THE GENERAL Hospital Corp.

Patentee before: Fluoropharma Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603